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Abstract
Frontotemporal dementia is a devastating neurodegenerative
disease causing stark alterations in personality and language.
Characterized by severe atrophy of the frontal and temporal
brain lobes, frontotemporal dementia (FTD) shows extreme
heterogeneity in clinical presentation, genetic causes, and
pathological ﬁndings. Like most neurodegenerative diseases,
the initial symptoms of FTD are subtle, but increase in severity
over time, as the disease progresses. Clinical progression is
paralleled by exacerbation of pathological ﬁndings and the
involvement of broader brain regions, which currently lack
mechanistic explanation. Yet, a ﬂurry of studies indicate that
protein aggregates accumulating in neurodegenerative dis-
eases can act as propagating entities, amplifying their
pathogenic conformation, in a way similar to infectious prions.
In this prion-centric view, FTD can be divided into three
subtypes, TDP-43 or FUS proteinopathy and tauopathy. Here,
we review the current evidence that FTD-linked pathology
propagates in a prion-like manner and discuss the implications
of these ﬁndings for disease progression and heterogeneity.
Keywords: FTD, FUS, prion-like spread, tau, TDP-43.
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This article is part of the Frontotemporal Dementia special issue.
Protein aggregation in the central nervous system is a
common feature of many neurodegenerative diseases.
Although the main protein component and primary affected
region can vary for each neurodegenerative disease, the
accumulation of misfolded proteins into insoluble aggre-
gates is a unifying hallmark and leads to progressive
dysfunction and death of neurons and glial cells. Despite
the diversity in clinical presentation, as well as pathological
ﬁndings, increasing evidence supports a common mecha-
nism driving neurodegeneration. Disease-related proteins
are transformed from their normal conformation into
ﬁbrillar or multimeric species that act as seeds of aggre-
gation and further sequester their native isoforms and
convert them into pathological molecules. This self-
perpetuating process leads to the formation of large aberrant
protein aggregates, which subsequently fragment into new
seeds that propagate their abnormal conformation in a
template-dependent manner within one cell, as well as
through the CNS by the release of seeds into the
extracellular space that can be taken up by neighboring
cells leading to the repetition of the propagation cycle
(Aguzzi 2009; Aguzzi and Rajendran 2009; Brundin et al.
2010; Goedert et al. 2010; Lee et al. 2010; Polymenidou
and Cleveland 2011, 2012; Jucker and Walker 2013;
Walker et al. 2013; Guo and Lee 2014; Walker and Jucker
2015; Sanders et al. 2016).
Such propagation mechanisms were long thought to be
exclusively associated with transmissible prion diseases, in
which template-directed protein misfolding leading to the
corruption of native molecules, is the basis for replication
of infectious prions. In bona ﬁde prion diseases (also called
transmissible spongiform encephalopathies), ingestion or
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internalization of the proteinaceous infectious agent (prion)
is sufﬁcient to transmit the disease between individuals
(Prusiner 1982). Prions replicate by recruiting the normal
cellular isoform of the prion protein, PrPC, into ordered
PrPSc-containing aggregates thus inducing a pathological
conformation. This continuous conversion into a highly
aggregative form triggers a widespread misfolding and
ﬁbril formation across the nervous system in a self-
perpetuating manner (Aguzzi and Polymenidou 2004;
Aguzzi 2009; Aguzzi and Rajendran 2009). Therefore, in
prion diseases, seeded aggregation causes neurodegenera-
tion and mice lacking the prion protein are completely
resistant to the disease (Bueler et al. 1993). Prion pathol-
ogy generally includes protein aggregation, neuronal loss,
gliosis, and spongiform degeneration (Aguzzi and Poly-
menidou 2004). However, variations in the disease pheno-
types, distinct histopathological signatures, varying
incubation periods and disease progression, were found to
be caused by different structural conformations of the
misfolded prion protein, which are referred to as strains
(Aguzzi et al. 2007).
Recently, the recognition of a similar propagation prin-
ciple in other, non-transmissible proteinopathies has led to
the term ‘prion-like’ (Goedert et al. 2010; Polymenidou and
Cleveland 2011; Jucker and Walker 2013; Guo and Lee
2014). The emerging realization that pathological aggre-
gates of amyloid-b, tau, a -synuclein, and others can act in
a prion-like manner has changed the view on disease
initiation and progression manner (Aguzzi 2009; Aguzzi
and Rajendran 2009; Goedert et al. 2010; Polymenidou and
Cleveland 2011, 2012; Jucker and Walker 2013; Guo and
Lee 2014). While the mechanisms triggering the initial
conversion of normally soluble proteins into pathogenic
polymers remain unresolved, substantial evidence showed
that aggregation seeds of amyloid-b (Meyer-Luehmann
et al. 2006), tau (Clavaguera et al. 2009), and a-synuclein
(Nonaka et al. 2010; Volpicelli-Daley et al. 2011; Luk
et al. 2012) can induce template-dependent misfolding of
native proteins in vitro and in vivo. Moreover, cell-to-cell
transmission of protein aggregates has also been proven for
amyloid-b, tau, a-synuclein, SOD-1, and TARDBP-binding
protein, 43 kD (TDP-43) (Clavaguera et al. 2009; Grad
et al. 2011; Nath et al. 2012; Nonaka et al. 2013), although
both the exact spreading mechanism and nature of the
transmissible entity have not been fully resolved.
These ﬁndings support an attractive hypothesis for the
progressive nature of these diseases. Indeed, most neurode-
generative disorders are initially subtle but progress relent-
lessly, often exhibiting a clear spatiotemporal involvement of
distinct, but interconnected regions of the nervous system.
The molecular entity responsible for this disease spread
remains controversial, but seeded aggregation of pathogenic
proteins, which lead to neurotoxicity and eventually cell
death, may well explain these phenomena.
Frontotemporal dementia is characterized by
complex genetic causes and heterogeneous clinical
presentation
Frontotemporal dementia (FTD) is the second most frequent
cause of presenile dementia with age of onset typically
between 45 and 65 years. It is associated with frontal and
temporal lobe atrophy leading to a progressive dysfunction in
behavior, personality, and language, mostly with preserva-
tion of memory (Neary et al. 1998; McKhann et al. 2001).
The clinical phenotypes can be classiﬁed into behavioral
variant FTD (bvFTD) and two versions of primary progres-
sive aphasia: semantic dementia and progressive non-ﬂuent
aphasia (Gorno-Tempini et al. 2011; Rascovsky et al. 2011).
Importantly, FTD clinically overlaps with amyotrophic
lateral sclerosis (ALS), which is the most common motor
neuron degeneration. Indeed, an estimated ~ 20% of FTD
patients develop progressive paralysis and ~ 20% of ALS
patients present personality changes compatible with FTD
(Caselli et al. 1993; Neary et al. 2000; Lomen-Hoerth et al.
2002; Ng et al. 2015).
FTD is a heritable disease with approximately 25–50% of
cases reporting a family history and thus indicating a strong
genetic component (Rohrer et al. 2009). The ﬁrst FTD-
associated mutation was found in the microtubule-associated
protein tau (MAPT) gene on chromosome 17 in 1998 (Hutton
et al. 1998). Up till now over 50 different causal MAPT
mutations were found accounting for 5–20% of familial FTD
cases (Rohrer et al. 2009; Spillantini and Goedert 2013). In
2006mutations in the progranulin (GRN) gene – coincidentally
near MAPT on chromosome 17 – were identiﬁed to cause an
even larger proportion of familial FTD cases (Baker et al.
2006;Cruts et al. 2006). Severalmuch less commonmutations
in the valosin-containing protein (VCP) gene (Watts et al.
2004), the gene encoding charged multivesicular body protein
2B (Skibinski et al. 2005; Parkinson et al. 2006) and others
have since been discovered. A major breakthrough in FTD
genetics was the recognition of hexanucleotide repeat expan-
sions in a non-coding region of the chromosome 9 open
reading frame 72 (C9ORF72) gene, which cause ~ 25% of all
familial and ~ 6% of sporadic FTD cases, making it the most
common genetic cause (DeJesus-Hernandez et al. 2011;
Renton et al. 2011). In people of European ancestry,
C9ORF72 hexanucleotide repeat expansions also cause
~ 40% of familial ALS and ~ 7% of sporadic ALS, whereas
up to 90% of families with concurrent ALS and FTD carry
C9ORF72 mutations (Majounie et al. 2012) (Table 1).
Frontotemporal dementia is subclassified into three
distinct and non-overlapping pathologies: tau,
TDP-43 and FUS
The neuropathology of clinical FTD also reﬂects the
heterogeneity of the disorder. While frontotemporal lobar
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degeneration (FTLD) is the common underlying pathology of
clinical FTD, several distinct disease types exist, subclassi-
ﬁed based on the deposited protein found in abnormal
intracellular inclusions (Mackenzie and Rademakers 2007;
Mackenzie et al. 2010). The ﬁrst subgroup includes ~ 40%
of all FTLD cases and is deﬁned by hyperphosphorylated tau
inclusions in neurons and glia and is classiﬁed as FTLD-tau.
However, most cases of FTD are not associated with tau
pathology and are instead deﬁned by neuronal inclusions
originally identiﬁed by their immunoreactivity for ubiquitin
and consequently termed FTLD-U (Josephs et al. 2004;
Mackenzie et al. 2006). A major breakthrough followed
when TDP-43 was found to be the main component in
ubiquitinated pathological inclusions in most FTLD-U cases,
as well as in the majority of ALS cases (Arai et al. 2006;
Neumann et al. 2006). This ﬁnding not only resulted in a
new subtype of FTD termed FTLD-TDP (Neumann et al.
2006), but it also provided a strong connection between the
two disorders that had clinically been connected before
(Caselli et al. 1993; Neary et al. 1998; Lomen-Hoerth et al.
2002). An overlapping molecular pathogenesis was further
veriﬁed when the majority of tau- or TDP-43-negative
inclusions were shown to be immunoreactive for a protein
called fused in sarcoma (FUS) (Neumann et al. 2009a)
shortly after FUS mutations had been detected as a cause of
autosomal dominant ALS (Kwiatkowski et al. 2009; Vance
et al. 2009). Interestingly, two other related DNA/RNA-
binding proteins Ewing sarcoma protein (EWS) and TATA-
binding protein-associated factor 15 were recently found to
co-aggregate in FUS-positive inclusions in FTLD-FUS
(Neumann et al. 2011).
While TDP-43 and FUS pathology connect FTD and ALS,
FTLD-tau also shares its misfolded tau tangles with the most
prominent neurodegenerative disorder, namely Alzheimer’s
disease (AD) (Querfurth and LaFerla 2010), whose primary
pathology are insoluble, extracellular amyloid-b plaques.
Pathophysiological roles of proteins involved in FTD
The microtubule-associated protein tau forms toxic fibrils in
FTD
In its natively unfolded form, tau protein is involved in
microtubule formation and stabilization, as well as the
regulation of axonal transport (Clavaguera et al. 2013). In
humans, tau is abundantly found in neurons, where it
concentrates in axons (Fig. 1a), but may also have a
physiological function in dendrites (Binder et al. 1985).
Six tau isoforms are expressed from a single gene (MAPT) by
alternative mRNA splicing in the human brain (Goedert
et al. 1989; Andreadis et al. 1992), each differing from the
other by inclusion or exclusion of a 29- or 58-amino acid
N-terminal insert and a 31-amino acid repeat in the
microtubule-binding domain of tau, encoded by exon 10.
Two major groups of tau isoforms can be distinguished: three
isoforms with four exon 10 repeat sequences (4-repeat-tau,
4R) and three others with three repeat sequences (3-repeat
tau, 3R) (Goedert et al. 1989).
In several disorders called tauopathies, the protein
becomes hyperphosphorylated and forms insoluble ﬁlamen-
tous inclusions making tau the most commonly misfolded
protein in neurodegenerative diseases. Tauopathies include
Alzheimer’s disease, tangle-only dementia and FTLD-tau
including frontotemporal dementia and parkinsonism linked
to chromosome 17 (FTDP-17 MAPT), Pick’s disease,
argyrophilic grain disease, as well as progressive supranu-
clear palsy and corticobasal degeneration (Clavaguera et al.
2013; Lashley et al. 2015a). Hyperphosphorylation promotes
the dissociation of tau from microtubules and is an early
event in the process of tau aggregation. Hyperphosphorylated
tau was shown to mislocalize to dendritic spines leading to
synaptic abnormalities early in disease (Braak et al. 1994;
Cochran et al. 2014). Many phosphorylation sites as well as
responsible protein kinases and phosphatases have been
identiﬁed and it has been suggested that tau may ﬁrst misfold
in human tauopathies, thus making it more accessible to
protein kinases and less to protein phosphatases, leading to
its hyperphosphorylation and increased aggregation propen-
sity (Hanger et al. 2009; Clavaguera et al. 2013). In
addition, a number of other disease-associated post-transla-
tional modiﬁcations of tau have been described, which
include ubiquitination, acetylation, N-glycosylation,
O-GlcNAcylation, nitration, prolyl isomerization, sumoyla-
tion, and truncation (Fig. 1b) (Lashley et al. 2015b; Wang
and Mandelkow 2016).
Tau ﬁlaments possess a cross-b structure characteristic of
amyloid ﬁbrils and it is widely accepted that their formation
in speciﬁc brain regions contributes to disease pathogenesis
and can induce neurotoxicity and cellular dysfunction.
Insoluble tau aggregates can be found in numerous disorders,
where they exhibit a range of morphologies (Crowther and
Goedert 2000), with speciﬁc conformers of distinct isoform
types giving rise to distinguishable cellular tau pathologies.
For instance, a mixture of 3R and 4R tau form neuroﬁbrillary
tangles can be observed in the somatodendritic compartment,
as well as neuropil threads in the distal axon and dendrites in
AD. Conversely, in other tauopathies only one isoform is the
predominant species, as reﬂected by characteristic ultrastruc-
tural morphologies that can be found in either exclusively
neuronal or both neuronal and glial tau ﬁlaments (Goedert
et al. 1992).
FTDP-17 MAPT presents a special case of tauopathy in
which mutations in the MAPT gene trigger abundant tau
pathology (Hutton et al. 1998; Poorkaj et al. 1998; Spillan-
tini et al. 1998; Goedert and Jakes 2005). Depending on the
mutation, ﬁlamentous inclusions consist primarily of 3R, 4R
or a mixture of all six tau isoforms and are deposited in
neurons and glial cells (Ghetti et al. 2015). Further FTLD
subtypes are also characterized by speciﬁc tau pathology
© 2016 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
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with typically one isoform subtype: pick bodies composed
primarily of 3R tau in Pick’s disease (Delacourte et al.
1996), tufted astrocytes and numerous neuroﬁbrillary tangles
in subcortical nuclei in progressive supranuclear palsy
(Flament et al. 1991), and 4R tau astrocytic plaques with
abundant thread pathology in corticobasal degeneration
(Ksiezak-Reding et al. 1994). As a primary tauopathy that
leads to severe neuronal loss, astrocytic gliosis, and spon-
giosis (Morris et al. 2001), FTLD-tau demonstrates that
dysfunction and subsequent accumulation of the tau protein
FTLD-Tau
SUF-DLTF PDT-DLTF
 Healthy neuron
RRM1 RRM2 Glycine rich region
414472262191671601
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Fig. 1 The three main types of FTD pathology are characterized by
the accumulation of distinct protein aggregates. (a) In healthy neurons,
tau (green crescent) is mainly distributed in axons and regulates
microtubule stability. TDP-43 (red) and FUS (yellow) are primarily
found in the nucleus, where they are involved in several steps of RNA
metabolism. In the cytoplasm, both proteins participate in dynamic
RNA granules, facilitating axonal transport or forming as part of the cell
stress response. (b) In pathological conditions of FTLD-tau, the protein
is dissociated from microtubules and accumulates into pathogenic
tangles in the cytoplasm. Mutations in the microtubule-binding region
of the microtubule-associated protein tau (MAPT) gene are found
FTLD-17 MAPT and can lead to splicing changes and decreased
microtubule-binding afﬁnity. Hyperphosphorylation (P) and other post-
translational modiﬁcations (N-Glyc (N‑glycosylation), Ac (Acetylation),
Ub (Ubiquitination) can further enhance the detachment, resulting in
microtubule disassembly and the formation of tau aggregates in the
cytoplasm (example modiﬁcation sites are shown). (c) In FTLD-TDP-
43 several underlying genetic causes (GRN, VCP, TDP-43, C9ORF72
mutations) and sporadic cases are linked by a common TDP-43
pathology. TDP-43 undergoes several disease-associated modiﬁca-
tions including phosphorylation, ubiquitination and C-terminal cleavage
and forms pathogenic inclusions in the cytoplasm leading to a
redistribution of the protein, associated with nuclear clearance. (d)
Although called FTLD-FUS, all FET proteins have now been found to
co-aggregate in ubiquitinated inclusions in severe cases of sporadic
FTD. Factors impairing the nuclear import of these proteins might lead
to cytoplasmic accumulation and following aggregation because of
strongly aggregation-prone low complexity domains. C9ORF72: chro-
mosome 9 open reading frame 72, E: Nuclear export signal, FET: FUS,
TAF-15, EWS protein interacting domain, FTD: frontotemporal demen-
tia, FTLD: frontotemporal lobar degeneration, FUS: fused in sarcoma,
L: nuclear localization signal, N1, N2: near-amino-terminal inserts, Q/
G/S/Y-rich: glutamine-glycine-serine-tyrosine rich region, R1, R2, R3,
R4: carboxy-terminal repeat domain, R/G-rich: arginine/glycine rich
region, RRM: RNA recognition motif, TDP-43: TAR DNA-binding
protein 43, VCP: valosin-containing protein, ZNF: zinc ﬁnger domain.
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per se sufﬁces to cause neurodegeneration and dementia
(Clavaguera et al. 2015).
The ribonuclear protein TDP-43 accumulates in cytoplasmic
aggregates in FTD and ALS
The discovery of TDP-43 as the main component of
ubiquitin-positive, cytoplasmic inclusions in approximately
50% of patients with FTD in 2006, rendered FTLD-TDP the
most frequent pathological subtype and enormous efforts
have been made ever since to uncover the underlying
mechanisms of TDP-43 pathogenesis. This ﬁnding also
strongly highlighted the pathological link between FTD and
ALS, which are now recognized as the two ends of the same
disease spectrum (Ling et al. 2013).
TDP-43 is a 414 amino acid protein encoded by the
TARDBP gene on chromosome 1. It is a ubiquitously
expressed and highly conserved heterogeneous nuclear
ribonucleoprotein, involved in multiple steps of RNA
maintenance and processing (Lagier-Tourenne et al. 2010;
Polymenidou et al. 2012). Two RNA recognition motifs
(RRM1 and RRM2) in the center of the protein enable
nucleic acid binding to UG-repeat sequences (Polymenidou
et al. 2011; Lukavsky et al. 2013), which might be
supported by an atypical ubiquitin-like domain, recently
found in the N-terminal part of the protein (Qin et al. 2014).
In the nucleus, TDP-43 plays a critical role in regulating
alternative RNA splicing, as well as modulating the levels of
long-intron containing RNAs important for neuronal activity
(Polymenidou et al. 2011; Lagier-Tourenne et al. 2012). By
regulating the stability of its own mRNA, TDP-43 can
autoregulate its protein levels (Ayala et al. 2011; Poly-
menidou et al. 2011; Bembich et al. 2014). In addition,
TDP-43 has recently been reported as a repressor of cryptic
exons, which, when included, trigger the degradation of
respective mRNAs (Ling et al. 2015). Although predomi-
nantly localized in the nucleus, TDP-43 contains a nuclear
localization signal (NLS) and a nuclear export signal, which
allow for classical Importin a/b-mediated shuttling (Winton
et al. 2008).
Indeed, several roles have been proposed for TDP-43
outside the nucleus (Fig. 1a) and nuclear efﬂux can be
inﬂuenced by both neuronal activity (Wang et al. 2008) and
stress (Bentmann et al. 2012). TDP-43 is a key component in
RNA transport granules and plays an important role in
regulating local translation at distal locations, a function that
is particularly important for neurons (Alami et al. 2014).
Furthermore, TDP-43 was shown to associate with stress
granules (Liu-Yesucevitz et al. 2010; Dewey et al. 2011;
Bentmann et al. 2012), which are non-membranous cyto-
plasmic foci composed of non-translating messenger ribonu-
cleoprotein complexes that transiently form in cells upon
stress, thus selectively stalling protein synthesis (Anderson
and Kedersha 2009). The C-terminus of TDP-43 harbors an
aggregation-prone glycine-rich region important for protein–
protein interactions (Buratti et al. 2005) that is necessary for
its recruitment into stress granules, as deletion of this domain
excluded TDP-43 from these compartments (Dewey et al.
2011).
In disease, the physiological, predominantly nuclear
localization of TDP-43 is disturbed. Affected neurons and
glial cells show a mislocalization to the cytoplasm with the
formation of pathogenic inclusions (Fig. 1c) (Arai et al.
2006; Neumann et al. 2006; Igaz et al. 2008; Van Deerlin
et al. 2008). This cytoplasmic aggregation prevents its return
to the nucleus, leading to nuclear clearance. Moreover,
pathological TDP-43 inclusions present a speciﬁc
biochemical signature including polyubiquitination, hyper-
phosphorylation, and proteolytic cleavage of the highly
aggregation-prone C-terminus, which is co-deposited in the
cytoplasm along with the full-length protein (Arai et al.
2006; Neumann et al. 2006). Interestingly, the majority of
missense mutations linked to FTD or ALS in TDP-43 are
localized in the aggregation-prone C-terminal domain
(Lagier-Tourenne et al. 2010; Ling et al. 2013). The latter
also contains a glutamine/asparagine-rich low complexity or
prion-like domain that shares similarities with yeast prions
(Cushman et al. 2010; Fuentealba et al. 2010). Yeast prion
proteins contain regions that can switch their conformation
between an intrinsically unfolded and an aggregated state
that can impose its conformation to an unfolded counterpart,
in a mechanism similar to mammalian prions (Cushman
et al. 2010). Disease-linked point mutations in this already
aggregative prion-like domain of TDP-43 signiﬁcantly
increase its aggregation propensity, which hints to a
causative link between TDP-43 aggregation and disease
(Johnson et al. 2009; Guo et al. 2011; Molliex et al. 2015).
Importantly, in the cortex and hippocampus of FTLD-TDP
patients, phosphorylated C-terminal fragments of TDP-43
predominate over the full-length protein in the cytoplasmic
inclusions (Igaz et al. 2008), suggesting a key role in
neurodegeneration. The precise pathogenic mechanisms
triggered by TDP-43 remain unknown and it remains unclear
whether TDP-43 toxicity results from the loss of its normal
function, from direct toxicity of the cytoplasmic misfolded
protein deposits or a combination of the two possibilities
(Lagier-Tourenne et al. 2010; Polymenidou and Cleveland
2012; Ling et al. 2013).
Nucleocytoplasmic transport defects cause cytoplasmic
aggregation of FUS in FTD
Soon after the identiﬁcation of TDP-43 as a genetic and
pathological link between FTD and ALS, another DNA/
RNA-binding protein, named FUS – also referred to as TLS
for translocated in liposarcoma – was found in the patho-
logical inclusions of about 5–10% of FTLD (Neumann et al.
2009a) and approximately 4% of familial ALS cases
(Kwiatkowski et al. 2009; Vance et al. 2009). This discov-
ery provided further evidence that ALS and FTD are closely
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related disorders and emphasized the pathogenic involve-
ment of RNA-binding proteins in these conditions. However,
it quickly became clear that while in ALS-FUS missense
mutations in the FUS gene account for most familial ALS
and rare sporadic cases, no genetic alterations have been
associated with the vast majority of FTLD-FUS cases. Yet, in
the absence of FUS mutations, wild-type FUS misaccumu-
lates in distinct, atypical clinical subgroups of FTD patients
(Neumann et al. 2009a), namely neuronal intermediate
ﬁlament inclusion disease (Neumann et al. 2009b) and
basophilic inclusion body disease (Munoz et al. 2009)
without TDP-43 or tau pathology (Urwin et al. 2010).
FUS is a 526 amino acid, ubiquitously expressed ribonu-
cleoprotein and belongs to the FET (FUS, EWS, TAF-15)
family of proteins together with EWS and TAF-15 (Bertolotti
et al. 1996). It can bind nucleic acids through its C-terminal
part, which contains an RRM, two glycine/arginine-rich
motifs and a zinc ﬁnger domain. The N-terminal part of FUS
comprises a low complexity domain harboring a glutamine-
glycine-serine-tyrosine (Q/G/S/Y)-rich region and the R/G-
rich motifs, which render the protein highly aggregation-
prone (Sun et al. 2011) and which is predicted to attain
prion-like properties (Cushman et al. 2010; Polymenidou
and Cleveland 2011). An atypical nuclear localization signal
(PY-NLS) and a nuclear export signal allow Transportin-
mediated shuttling of the predominantly nuclear protein to
the cytoplasm (Lee et al. 2006), suggesting that FUS is
involved in RNA metabolism pathways that take place in
both cellular compartments (Lagier-Tourenne et al. 2010).
Being not only structurally, but also functionally similar to
TDP-43, FUS has been implicated in transcriptional repres-
sion, splicing regulation, and micro-RNA processing (Lagier-
Tourenne et al. 2010). Although TDP-43 and FUS bind a
distinct spectrum of RNAs, they share a preference for
mRNAs derived from genes with exceptionally long introns
and 45 common RNA targets, mostly important for normal
neuronal function, are signiﬁcantly down-regulated upon
depletion of either TDP-43 or FUS in the adult mouse brain
and in cultured human neurons (Polymenidou et al. 2011;
Lagier-Tourenne et al. 2012). Interestingly, several studies
show altered splicing of the MAPT mRNA upon FUS
depletion (Lagier-Tourenne et al. 2012). In primary neurons,
a loss of FUS leads to the expression of a longer tau isoform
(Orozco et al. 2012) that has also been found to be increased
in patients with FTD and Parkinsonism (Hutton et al. 1998).
In the cytoplasm, similar to TDP-43, FUS can partition in
stress granules (Bentmann et al. 2012) and plays a role in
RNA transport granules, which carry mRNAs to dendritic
spines for local translation (Kanai et al. 2004; Fujii and
Takumi 2005; Elvira et al. 2006). Moreover, FUS interacts
with the motor proteins kinesin and actin (Kanai et al. 2004;
Yoshimura et al. 2006) and is essential for spine morphology
(Fujii and Takumi 2005). Nevertheless, FUS predominantly
localizes to the nucleus of healthy cells, whereas it is
redistributed to the cytoplasm of affected cells, where it
accumulates and aggregates (Fig. 1d). This mislocalization
induces a partial loss of nuclear protein (Vance et al. 2009;
Mackenzie et al. 2010), albeit to a lesser extent compared to
TDP-43 proteinopathies. Strikingly, while both pathogenic
FUS (Neumann et al. 2009a; Urwin et al. 2010) and TDP-43
(Neumann et al. 2006) inclusions are immunoreactive for
p62 and ubiquitin, they seem mutually exclusive.
Evidence for prion-like behavior of FTD-associated
proteins
In vitro seeding and in vivo propagation and spreading of
misfolded tau was shown in multiple models
In its functional state tau is a hydrophilic protein that is
natively unfolded with very little secondary structure, which
makes it dynamic and highly soluble. Thus, its assembly into
highly ordered b-sheet structures that form insoluble amyloid
ﬁbers in disease is counterintuitive and several ﬁbrillization
enhancing tricks have been necessary to reproduce their
formation in vitro or in cell culture. Adding polyanionic
substances, RNA or fatty acids has been shown to promote
ﬁbril assembly of recombinant, full-length tau protein in vitro
by overcoming the nucleation barrier (Goedert 1996; Kam-
pers et al. 1996; Chirita et al. 2003). Indeed, tau ﬁbrillization
follows a nucleation-dependent mechanism, and initiating tau
aggregation with preformed tau ﬁbrils can bypass this
nucleation step and accelerate ﬁbrillization of monomeric
tau (Friedhoff et al. 1998). Similarly, highly soluble tau
resists aggregation despite high over-expression and sponta-
neous hyperphosphorylation in cultured cells. Addition of
minute quantities of preformed ﬁbrils, however, is sufﬁcient
to recruit large amounts of soluble tau into ﬁlamentous
inclusions with high efﬁciency (Friedhoff et al. 1998; Frost
et al. 2009). Thus, a mechanism of template-directed mis-
folding of soluble tau through recruitment to an initial
aggregated seed has been suggested to underlie the propa-
gation of tauopathies. Exogenously supplied recombinant tau
ﬁlaments can be internalized by cells and seed aggregation
by recruitment of endogenous tau into misfolded conforma-
tions (Frost et al. 2009; Guo and Lee 2011; Wu et al. 2013).
Newly misfolded tau was competent to initiate further
aggregation and could transfer between co-cultured cells.
The seed-dependent polymerization and transcellular propa-
gation of tau was also demonstrated by over-expression of an
aggregation-prone mutant in cells leading to amyloid
ﬁlaments that were released directly into the extracellular
space and subsequently taken up by co-cultured cells,
inducing tau ﬁbrillization.
The seeding and spreading of tau pathology via cell-to-cell
transfer of aggregates was also demonstrated in mouse
models in vivo. In an initial proof-of-principle study, brain
homogenates of transgenic mice expressing mutant human
tau with ﬁlamentous tauopathy were injected into mice
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transgenic for human wild-type tau (Clavaguera et al. 2009).
Upon inoculation, the originally inclusion-free mice devel-
oped ﬁlaments consisting of wild-type human tau in both
neurons and oligodendrocytes. This induced tau pathology
progressing over time from the injection site to neighboring
and more distant, anatomically connected brain regions.
Similar results were obtained using synthetic preformed tau
ﬁbrils to initiate extensive ﬁlamentous tau pathology in
young asymptomatic mutant human tau over-expressing
mice (Iba et al. 2013; Peeraer et al. 2015). Furthermore,
isolated tau oligomers from AD patient brains were able to
seed and propagate widespread amyloidogenic tau plaques
composed of endogenous murine tau, upon injection into the
hippocampus of normal C57BL/6 mice (Lasagna-Reeves
et al. 2012).
The spreading ability of tau pathology was further
conﬁrmed by cell-speciﬁc expression of the human mutant
tau in the entorhinal cortex. Several months after the
appearance of the ﬁrst tau inclusions in the transgene-
expressing neurons, distant axonally connected cells in the
hippocampus also developed ﬁlamentous tau pathology (de
Calignon et al. 2012; Liu et al. 2012). Indeed, several
studies have shown that induced tau pathology was able to
propagate to anatomically connected brain regions indicating
neuronal transport mechanisms and transsynaptic spread
involved in the proliferation of neuroﬁbrillary pathology (Iba
et al. 2013; Ahmed et al. 2014; Dujardin et al. 2014).
Neuronal activity can not only modulate tau protein secretion
into the extracellular space in culture (Yamada et al. 2014),
but it was further shown that synaptic contacts and neuronal
activation can signiﬁcantly potentiate neuron-to-neuron
propagation of tau pathology (Calafate et al. 2015).
While the above in vitro and in vivo evidence strongly
supports a template-dependent tau seeding and spreading
mechanism, a recent study pointed to a signiﬁcant deviation
from the classical prion-like mechanism, by demonstrating
that spreading of tau tangles does not depend on endogenous
tau expression in vivo (Wegmann et al. 2015). Importantly,
however, removing endogenous tau reduced neurotoxicity in
this paradigm, potentially highlighting the fact that tau
tangles do not equate the neurotoxic species. In agreement
with this view, tau was shown to misfold into smaller
aggregates prior to assembly into ﬁbrils, and these smaller
species, which are more efﬁciently taken up by neurons (Wu
et al. 2013), may be the primary neurotoxic moiety.
The low complexity domains of TDP-43 and FUS mediate the
formation of self-propagating, complex aggregates
Initial evidence suggests that a mechanism, similar to the
spreading and seeding of tau, could underlie TDP-43 and
FUS proteinopathies and several studies have demonstrated
that both proteins are intrinsically aggregation-prone and can
behave in a prion-like manner, both in vitro and in cell
culture. In vitro studies using recombinant, aggregated TDP-
43 (Furukawa et al. 2011) or FUS (Nomura et al. 2014)
showed that minute amounts were sufﬁcient to induce
misfolding and aggregation of their corresponding natively
folded protein, implicating template-dependent propagation.
The strong tendency of TDP-43 and FUS to aggregate is
mediated by the low complexity (Kato et al. 2012), or prion-
like (Cushman et al. 2010) domain found in both proteins;
the N-terminal part of FUS (amino acids 1-239) and the
C-terminal part of TDP-43 (amino acids 274-414), which
rank highly based on algorithms that identify aggregative and
prion-forming propensities (Alberti et al. 2009; Toombs
et al. 2010). FUS is characterized by an even higher
aggregation propensity than TDP-43 and it was shown to
spontaneously aggregate into pore-like oligomeric species
that rapidly assemble into ﬁlamentous structures in a cell-free
system within minutes (Couthouis et al. 2011; Sun et al.
2011). However, this capacity to aggregate is not enhanced
by disease-linked mutations affecting the NLS (Ju et al.
2011; Sun et al. 2011).
Over-expression of TDP-43 prion-like domain, induced
protein accumulation and cell toxicity (Furukawa et al. 2004;
Johnson et al. 2009; Zhang et al. 2009; Liu-Yesucevitz
et al. 2010; Guo et al. 2011; Pesiridis et al. 2011), whereas
deletion of the same domain from TDP-43 (Johnson et al.
2009; Furukawa et al. 2011) or FUS (Sun et al. 2011)
interfered with aggregate formation, indicating their require-
ment for efﬁcient seeding. While short recombinant or
synthetic peptides derived from the prion-like domain can
acquire toxic amyloid forms, puriﬁed full-length TDP-43
does not appear to have a classic amyloid structure, but rather
forms small pore-like oligomers and short ﬁbrils (Johnson
et al. 2009; Couthouis et al. 2011; Shimonaka et al. 2016),
which can cluster together in large complexes with resem-
blance to pathological inclusions (Fang et al. 2014). Going a
step further, it was demonstrated that aggregates reconsti-
tuted in vitro from recombinant wild-type or mutant TDP-43
or short synthetic peptides could seed aggregation of wild-
type or endogenously expressed protein in cell culture
(Furukawa et al. 2011; Shimonaka et al. 2016).
While this has not yet been shown for FUS, it was recently
reported that co-expression of mutant and wild-type FUS
induces aggregation of the otherwise soluble wild-type FUS
(Nomura et al. 2014). In this study, a rather rare mutation
located in the prion-like domain changed the aggregation
propensity of FUS and led to intranuclear inclusions, similar
to what can be found in cases of atypical FTLD-FUS
(Neumann et al. 2009a; Nomura et al. 2014).
Supporting the prion paradigm and self-templating prop-
erties of TDP-43 further, aggregated TDP-43 isolated from
ALS and FTD patient brains was able to act as a propagative
seed and induce protein misfolding and accumulation in
TDP-43 transfected cultured cells (Nonaka et al. 2013; Feiler
et al. 2015). Moreover, the induced TDP-43 aggregates
persisted within cells when the original pathogenic seed was
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no longer present and could then act as new misfolding
templates that exhibit properties consistent with prion-like
propagation (Nonaka et al. 2013). Recent evidence further-
more suggests that oligomeric TDP-43 can be transmitted
horizontally between cell somata likely via microvesicles,
trigger oligomerization, and exert toxicity in recipient cells
(Feiler et al. 2015). Neuron-to-neuron transmission experi-
ments further indicated both anterograde and retrograde
transsynaptic spreading of TDP-43 oligomers and provide
additional evidence of the propagative properties of TDP-43
(Feiler et al. 2015).
To date, no report of prion-like propagation of TDP-43 or
FUS in animal models could be found. However, a recent
mouse model expressing a regulatable human TDP-43
construct lacking the NLS indicated that existing intracellular
TDP-43 inclusions can be cleared in vivo, which can halt
further neurodegeneration (Walker et al. 2015). Suppression
of transgene expression after disease onset dramatically
decreased the accumulation of insoluble, phosphorylated,
cytoplasmic TDP-43, reversed the loss of endogenous
nuclear mouse TDP-43 and prevented further motor neuron
loss in this model (Walker et al. 2015). Similar results were
obtained in a study using an inducible TDP-43 transgene
with a point mutation where suppression of transgene
expression in mice with overt neurodegeneration for only
1 week was sufﬁcient to clear pathological TDP-43 and to
signiﬁcantly improve motor and behavioral deﬁcits (Ke et al.
2015). This suggests that the presence of intracellular
pathological TDP-43 at a certain point might not be sufﬁcient
for cell-to-cell spread and propagation of disease pathology
without a continuous pool of cytoplasmic TDP-43. However,
small quantities of transmitted pathological TDP-43 in
patients could lead to disease ampliﬁcation over extended
time periods (Walker et al. 2015).
While the prion-like domains of TDP-43 and FUS have
been incriminated for their aggregation propensity, other
protein regions seem to be contributing to this behavior. The
FUS prion-like domain alone is insufﬁcient to cause
aggregation, but requires the RNA-binding motif and a
glycine-rich RGG domain (Sun et al. 2011). Intriguingly,
this RGG domain contains a short low complexity region
(amino acids 391–407), which might allow the protein to
self-aggregate using its two prion-like domains (Gitler and
Shorter 2011). Moreover, in contrast to most observations
focusing on the C-terminal domain of TDP-43, two recent
studies highlight the signiﬁcance of the N-terminal region,
which was reported to mediate RNA binding thereby
ensuring proper protein function, such as splicing regulation,
as well as promoting aggregation (Zhang et al. 2013; Qin
et al. 2014). This unexpected function is facilitated by an
unusual structural switch from a folded ubiquitin-like domain
upon DNA binding in low protein concentrations to an
unfolded and aggregation-prone structure with increasing
protein concentrations (Qin et al. 2014).
Increase in local concentration and RNA association in stress
granules may initiate TDP-43 and FUS aggregation
The mechanisms driving the onset of FTD and many other
neurodegenerative disorders still remain unknown. While
mutations in TDP-43 seem to facilitate protein aggregation
in subcellular compartments, alternative etiologies may
contribute to pathogenesis in the majority of tau-negative
cases including sporadic forms of FTLD-TDP and familial
forms with GRN, C9ORF72, or VCP mutations all leading
to a similar TDP-43 pathology. Likewise, no genetic cause
has been identiﬁed in aggressive forms of FTLD-FUS.
Thus, attractive candidates to trigger disease are environ-
mental stimuli, such as cellular stress and the implication of
both TDP-43 (Colombrita et al. 2009; Moisse et al. 2009;
Liu-Yesucevitz et al. 2010; McDonald et al. 2011) and
FUS (Andersson et al. 2008; Dormann et al. 2010; Bent-
mann et al. 2012) in stress granule assembly offers a
plausible mechanism for aggregate nucleation and thereby,
disease initiation and possible seeding (Ito and Suzuki
2011).
Indeed, the formation of stress granules per se is mediated
by the ordered aggregation of TIA-1, an essential stress
granule component that possesses a prion-like domain, which
is not only required for TIA-10s nucleation, but can even be
replaced by another prion-like domain from a yeast prion
protein without affecting the size or number of stress
granules (Gilks et al. 2004). Aggregated TIA-1 can then
recruit mRNAs and other proteins, including TDP-43
(Colombrita et al. 2009; Liu-Yesucevitz et al. 2010;
McDonald et al. 2011) and FUS (Andersson et al. 2008)
into these cytoplasmic foci, which are transiently formed and
resolved in a strictly regulated manner under physiological
conditions (Buchan and Parker 2009; Wolozin 2012).
However, since high protein concentration is a main
determinant for protein aggregation, the increase in local
TDP-43 and FUS concentration within stress granules could
facilitate aggregation initiation. With the persistence of
cellular stress during aging, these granules may act as
precursors of pathologic inclusions, which may transform
into irreversible aggregates and form seeds of aggregation
(Polymenidou and Cleveland 2011; Maniecka and Poly-
menidou 2015). This mechanism may be further assisted by
the association with RNA molecules that can act as scaffolds
mediating the ordered aggregation of TDP-43 and FUS
within these cytoplasmic granules. Indeed, the main RNA-
binding region of FUS is the arginine-glycine-glycine zinc
ﬁnger domain, which is most important for stress granule
recruitment, while both RRM1 and the C-terminal glycine-
rich domain of TDP-43 are required for SG localization
(Bentmann et al. 2012). Furthermore, the scaffolding capac-
ity of RNA has been shown in the in vitro aggregation of the
mammalian prion protein (Deleault et al. 2003), as RNA and
phospholipids were necessary to generate infectious prions
with puriﬁed PrP (Wang et al. 2010). In addition, RNA was
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shown to mediate the formation of ﬁbril-like FUS assemblies
in vitro (Schwartz et al. 2013).
After the initiation phase, another characteristic shared by
TDP-43 and FUS could potentially contribute to their self-
perpetuating aggregation. The levels of both proteins are
strongly autoregulated through binding to their own mRNA
transcripts and regulating the RNA processing pathways
(Ayala et al. 2011; Polymenidou et al. 2011; Lagier-
Tourenne et al. 2012; Zhou et al. 2013). The formation of
pre-inclusions with sequestration of TDP-43 or FUS in the
cytoplasm would cause a reduction in nuclear protein, which
in turn would lead to increased levels of stable TARDBP or
FUS transcripts. Consequently and enhanced by the addi-
tional cell stress because of the formation of pre-inclusions,
TDP-43 or FUS protein levels rise providing abundant
substrate for continuous seeded aggregation, and thus
contributing to the growth of pathogenic deposits (Maniecka
and Polymenidou 2015). Increased levels of TDP-43 mRNA
measured in the brains of patients affected by various forms
of FTLD (Mishra et al. 2007; Chen-Plotkin et al. 2008)
suggests that such a feed-forward mechanism could enable
and enhance aggregate propagation.
Interestingly, both TDP-43 and FUS were found to
colocalize with stress granule proteins, including TIA-1
(Fujita et al. 2008; Liu-Yesucevitz et al. 2010), PABP-1
(Bentmann et al. 2012), and eIF3 (Liu-Yesucevitz et al.
2010) in ALS and FTD patients. Several stressors, such as
oxidative, osmotic, heat shock, and ER stress were able to
recapitulate the cytoplasmic redistribution and stress granule
association of TDP-43 (Colombrita et al. 2009; Liu-Yesu-
cevitz et al. 2010; Dewey et al. 2011; McDonald et al.
2011; Leggett et al. 2012). Importantly, some of these stress-
induced granules turned into insoluble aggregates and were
shown to persist after removal of the stressor (Dewey et al.
2011; Cohen et al. 2015; Feiler et al. 2015; Kabuta et al.
2015). Importantly, recent elegant biophysical studies (Burke
et al. 2015; Molliex et al. 2015; Patel et al. 2015) support
the hypothesis that soluble and dynamic stress granules can
transform into insoluble and irreversible aggregates in vitro.
Indeed, FUS and other RNA-binding proteins containing low
complexity domains can form dynamic liquid-like assemblies
in vitro (Han et al. 2012; Kato et al. 2012; Burke et al.
2015; Molliex et al. 2015; Patel et al. 2015) that resemble
ﬂexible cellular stress granules. Over time these dynamic
assemblies can mature into rigid, large protein structures,
reminiscent to pathological protein aggregates seen in
patients (Burke et al. 2015; Molliex et al. 2015; Patel et al.
2015). Taken together, evidence suggests that stress granules
may initiate or facilitate TDP-43 and FUS seeding within the
cytoplasm of diseased cells.
Notably, despite its unrelated structure and function, tau
has also been shown to associate with stress granule proteins
(Vanderweyde et al. 2012). Patients with FTLD-tau and AD
show large amounts of stress granules that colocalize with
tau tangles and induction of stress granules in cells over-
expressing tau and TIA-1 appears to be able to induce tau
pathology (Vanderweyde et al. 2012). Furthermore, tau
binding on RNA was shown to promote its aggregation into
paired helical ﬁlaments (Kampers et al. 1996). Thus, stress
granule formation is implicated in all subtypes of FTD
(Vanderweyde et al. 2012).
Molecular mechanisms of cell-to-cell spread: what
is transmitted and how?
Pathways of transcellular transport include active and
passive mechanisms of release and uptake
Cell-to-cell propagation requires speciﬁc transmission events
and the mechanisms by which misfolded protein complexes
spread from one neuron to the next have not been fully
determined. The protein seed needs to be released from one
cell and get internalized by another where it has to be able to
convert endogenous monomers to a pathogenic conformation
and thus amplify. The properties of the transmitted protein
aggregates, as well as the exact mechanisms, which underlie
transcellular spread are still largely unknown and highly
debated. The latter may include exocytosis, vesicle mediated
(exosomes or pre-synaptic vesicles) or passive release by
degeneration of a cell. The receiving neuron might internal-
ize the protein by macropinocytosis, receptor-mediated
endocytosis, vesicle membrane fusion or direct penetration.
Direct transfer could also happen via tunneling nanotubes
(Fig. 2).
Although tau is predominantly an intracellular protein,
multiple studies have shown that it is physiologically
released into the extracellular space in cell culture and the
mouse brain (Pooler et al. 2013b). It has been detected in the
cerebrospinal ﬂuid (CSF) and the brain interstitial ﬂuid of
wild-type and transgenic mice (Yamada et al. 2011) and both
healthy and AD individuals (Arai et al. 1995). It is, however,
still controversial, whether tau is released in a free soluble
form or inside membrane vesicles. Several studies have
detected tau in various kinds of vesicles including exosomes
(Saman et al. 2012), ectosomes (Dujardin et al. 2014),
microvesicles (Simon et al. 2012), and synaptic vesicles
(Pooler et al. 2013a) in cultured cells and animal models.
Consistent with these models, tau was also found in
exosomes in the CSF of healthy controls and AD patients
(Saman et al. 2012), however, no data are available on
FTLD-tau patients. In addition, free tau seems to be released
via unconventional secretory and vesicle independent mech-
anisms (Karch et al. 2012; Chai et al. 2012).
Increased levels of TDP-43 have been detected in the CSF
of ALS patients (Kasai et al. 2009), with some full-length
TDP-43 and TDP-43 CTFs being found in the exosomal
fraction (Feneberg et al. 2014; Ding et al. 2015). Cell
culture models also suggest the possible transfer of TDP-43
via exosomes (Nonaka et al. 2013) or microvesicles (Feiler
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et al. 2015) and tunneling nanotubes (Ding et al. 2015).
While many of the above mechanisms may also apply to
FUS, there is currently no experimental evidence on the
extent and mode or release and uptake of FUS aggregates by
cells.
Extracellularly released protein needs to be taken up by
surrounding cells. Macropinocytosis, as a form of ﬂuid-phase
uptake, has been proposed as a mechanism for several
extracellular aggregates including tau (Frost et al. 2009;
Holmes et al. 2013). This process relies on heparan sulfate
proteoglycans (HSPGs) as membrane receptors for binding,
internalization, seeding, and transcellular propagation of tau
(Holmes et al. 2013). While this process involves direct
binding of free tau seeds, a new study suggests that HSPGs can
also facilitate the internalization of exosomes (Christianson
et al. 2013), and might thus offer penetration and propagation
mechanisms for many other aggregated protein species.
Intriguingly, TDP-43 seems to be much more efﬁciently taken
up when packaged into microvesicles/exosomes in cultured
cells and primary neurons (Feiler et al. 2015). FTD-associated
proteins might take advantage of several of these mechanisms
simultaneously to spread between neighboring cell bodies or
synaptically connected neurons.
The importance of transcellular spreading via release and
reuptake in disease propagation and pathology has been
demonstrated using extracellular anti-tau antibodies. Several
antibodies have been shown to prevent tau spreading in cell
culture (Kfoury et al. 2012), as well as in mouse models
(Chai et al. 2011; Yanamandra et al. 2013, 2015) by
blocking uptake of certain types of tau ﬁbrils and promoting
clearance by microglia (Funk et al. 2015). These studies
strongly support the beneﬁcial role of tau immunotherapy as
it leads to reduced tau pathology, decreased seeding activity,
as well as improved cognitive deﬁcits in animal models
(Boutajangout et al. 2011; Chai et al. 2011; Yanamandra
et al. 2013, 2015).
(a)
(b)
(c)
2. Exosomal release
3. Synaptic release
MVB
pathological tau
pathological TDP-43
HSPGs
receptor
1. Exocytosis
4. Cell membrane degeneration
9. Nanotubes
8. Vesicle fusion
5. Endocytosis
7. Direct penetration 
6. Macropinocytosis
Fig. 2 Proximity-dependent and transsynaptic mechanisms of cell-to-
cell spread. The transmission of pathological seeds (tau: green;
TARDBP-binding protein, 43 kD (TDP-43): red) may happen between
neighboring cells within the same brain region in a proximity-dependent
pattern through active release (a) or passive leakage (c) whereas
spreading between distant anatomically connected brain regions may
rely on synaptic connectivity (b). The protein seeds may be released
from the donor cell (gray) via exocytosis (1), packaged into vesicles
such as exosomes (released from multivesicular bodies (MVBs)) (2) or
dispensed by synaptic vesicles (3), with all these mechanisms having
been suggested for tau and TDP-43. Furthermore, pre-synaptic
membrane leakage because of the degeneration of neurons can lead
to extracellular protein seeds (4). Once released, free protein seeds
may be internalized by receptor-mediated endocytosis (5) or heparan
sulfate proteoglycan (HSPG)-dependent macropinocytosis (6) or
directly penetrate the recipient cell (blue) (7). Membrane-coated seeds
can fuse with the receiving neuronal membrane (8). Direct transfer
between two cells could also happen via tunneling nanotubes (9).
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While promoting microglial aggregate uptake and clear-
ance decreased tau pathology in some studies, microglia
have also been found to promote propagation and disease
progression by phagocytosing and secreting tau protein in
exosomes (Asai et al. 2015). Depleting microglia or
inhibiting exosome synthesis was shown to signiﬁcantly
reduce tau propagation in vitro and in vivo (Asai et al.
2015).
Properties of transporting pathologic species are elusive
However, it is still unclear which protein species –
monomer, oligomer, or aggregate – can efﬁciently spread
and is responsible for transmitting pathology. Most extra-
cellular tau seems to be monomeric and while a recent study
suggests that trimers are the minimal unit of propagation
leaving monomers unlikely to spread pathology as they are
not spontaneously internalized (Mirbaha et al. 2015),
another group showed that monomeric tau is sufﬁcient to
initiate the nucleation of aggregate seeds in an HSPG-
independent manner (Michel et al. 2014). Further studies,
however, found no seeding activity for monomeric tau and
small oligomers, but showed the requirement for short
ﬁbrils (Jackson et al. 2016) or even very large, high
molecular weight species to transfer pathology efﬁciently
(Takeda et al. 2015).
The properties of the propagation efﬁcient TDP-43
particles are even less deﬁned. Recent evidence suggests
that TDP-43 can be transmitted horizontally in a dimeric/
oligomeric form using the microsome/exosome pathway
(Feiler et al. 2015). However, in this setting, TDP-43 dimers/
oligomers might represent a physiological state, different
from the small pore-like oligomeric structures found in
transgenic mice and FTD patients (Fang et al. 2014).
Furthermore, it has not been explored if TDP-43 particles
are released in a complex bound to nucleic acids or
interacting proteins. This would pose an interesting question
with regard to uptake mechanisms and further oligomeriza-
tion and seeding properties in the recipient cell.
Neurodegenerative changes gradually intensify
from most to less affected regions of the human
nervous system
Disease staging studies and implications for disease
progression
Intriguingly, many neurodegenerative diseases not only share
the general pathology of misfolded protein aggregates, but
also clinically present a characteristic progressive nature.
Progressing disease symptoms have therefore been hypoth-
esized to coincide with the propagation of pathology across
anatomically connected regions of the nervous system.
Indeed, neuropathological studies have recently recognized
that characteristic anatomical patterns can be found in
various neurodegenerative diseases and that the progression
of these stereotypical patterns is linked to an increasing
severity of the disease phenotype (Brettschneider et al.
2015). Staging studies could show that pathological events
initiate very early in a certain CNS area and progress
sequentially in a topographically predicted manner through
anatomical connections.
Early staging attempts of disease progression were based
on clinical signs and brain atrophy (Broe et al. 2003; Mioshi
et al. 2010; Kril and Halliday 2011). One of the best
described cases of progressive neurodegenerative changes is
ALS, where motor neuron loss was shown to initiate focally
and progress gradually away from this initial focus, which
generally coincides with the spinal cord level that deﬁnes the
original symptoms (Ravits et al. 2007a,b; Ravits and La
Spada 2009; Ravits 2014). Later efforts concentrated on
analyzing aggregate size and number of affected cells with
pathological inclusions as molecular correlates of the
systematic symptom spread. Indeed, a gradual distribution
of pathological TDP-43 aggregates was found in ALS and
FTD patients throughout the neuraxis (Geser et al. 2009).
Furthermore, a four stage model describing the sequential
spread of TDP-43 pathology in ALS was proposed based on
the progressive dissemination of intraneuronal phospho-
TDP-43 positive aggregates. According to this model, ALS
starts in the cerebral neocortex and the somatomotor neurons
of the spinal cord and the lower brainstem and spreads in an
anterograde manner along corticofugal axonal pathways to
connected subcortical areas and distant CNS sites (Braak
et al. 2013; Brettschneider et al. 2013). Similarly, a recent
study focused on phospho-TDP-43 positive inclusions in
bvFTD suggests a sequential spreading pattern along a
fronto-occipital gradient with the ﬁrst lesions starting in
orbitofrontal areas and the amygdala, followed by lesions
appearing later in premotor, primary motor, parietal and,
ﬁnally, occipital areas of the cortex (Brettschneider et al.
2014).
While, the expansion and stereotypical spread of tau
pathology across the nervous system have been clearly
characterized in AD (Braak and Braak 1995; Braak et al.
2006) and chronic traumatic encephalopathy (Braak and
Braak 1995; Geddes et al. 1999; Braak et al. 2006; McKee
et al. 2013), one recent study also relates the neuropatho-
logical progression of tauopathy with clinical symptoms of
bvFTD. Spreading sequentially from the frontotemporal and
neocortical regions to the subcortical structures, the primary
motor cortex and ﬁnally the visual cortex tau pathology
reﬂected the evolution of clinical symptoms and directly
correlated with disease duration (Irwin et al. 2016).
Collectively, the above data support the spatiotemporal
spread of pathologic aggregates throughout the nervous
system, although the alternative hypothesis of a temporally
selective regional vulnerability of neurons to lesion forma-
tion (Walsh and Selkoe 2016) has not been formally
excluded.
© 2016 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
International Society for Neurochemistry, J. Neurochem. (2016) 138 (Suppl. 1), 163--183
174 E.-M. Hock and M. Polymenidou
Protein aggregates preferentially spread across neuronal
networks in FTD
More and more evidence supports the idea that neuronal
connectivity deﬁnes disease-spreading pathways and that
pathology is transmitted along neural networks through
propagation of self-templating misfolded protein aggregates.
After disease origination at an initial focal point, anatomi-
cally neighboring regions may lie at risk of involvement
through proximity-dependent transfer of released patholog-
ical seeds. However, recent imaging studies relating degen-
eration patterns to neural connectivity suggest a ‘network-
based neurodegeneration’ hypothesis supporting the model
of transsynaptic propagation of toxicity along functionally
and anatomically connected networks (Raj et al. 2012; Zhou
et al. 2012; Agosta et al. 2015). For each disease type
speciﬁc neural networks emerged with their critical center
areas and functional and anatomical connectivity proﬁles
resembling disease-associated atrophy patterns. Modeling
analysis thus supports a pathology model of transneuronal
spread based on connectional strength that deﬁnes disease
vulnerability (Zhou et al. 2012).
In bvFTD progressive atrophy patterns were found to
resemble a network called the salience network. The latter,
which includes the anterior cingulate cortex and frontoinsula,
as well as the amygdala and striatum (Rosen et al. 2002; Broe
et al. 2003; Seeley 2008), is important for socioemotional
tasks relying on attentional selection and self-regulation of
behavior (Seeley et al. 2007). bvFTD patients exhibit reduced
connectivity in the salience network,which has been correlated
with clinical severity, apathy, and disinhibition scores (Zhou
et al. 2010; Filippi et al. 2013). Furthermore, changes in the
white matter tracts connecting key regions of the salience
network reﬂect the propagation of pathology and have been
proposed as a marker to assess in vivo spreading of patholog-
ical proteins (Agosta et al. 2012; Lam et al. 2014).
In the context of cell-to-cell propagation of toxic seeds, the
network hypothesis offers a plausible route for the pathological
spread that deﬁnes clinical presentation. The original site of
pathologymay determine the network involved and eventually
the clinical phenotype (Sanders et al. 2016). Inoculation
studies (Iba et al. 2013), as well as region-selective expression
ofmutant tau (deCalignon et al. 2012; Liu et al. 2012) inmice
strongly support the selective spreading of pathology along
known anatomical networks, Indeed, pathology in the entorhi-
nal cortex was induced by tau pathology initiated in the
hippocampus, while injection into the striatum led to pathol-
ogy in the substantia nigra and the thalamus (de Calignon et al.
2012; Liu et al. 2012; Iba et al. 2013).
Multiple conformations of pathogenic protein
assemblies may contribute to disease heterogeneity
Aside from the network-speciﬁc involvement, the molecular
principles of the prion paradigm may also offer an
explanation for the high variability in pathology and clinical
presentation in neurodegenerative diseases. Indeed, the
concept of strains is well established for prion diseases,
where several distinct self-propagating conformers or strains
underlie different pathological manifestations and disease
phenotypes in humans and mice (Aguzzi et al. 2007).
Recently, other neurodegenerative disease-associated pro-
teins are also revealing strain-like properties including
a-synuclein (Guo et al. 2013) and Ab (Petkova et al.
2005; Heilbronner et al. 2013). Strain manifestation seems
particularly plausible for tau, given the variety of clinical and
neuropathological characteristics in tauopathies with differ-
ences in regional involvement, disease duration, age of onset,
isoform expression, and ﬁbril morphology.
Indeed, seeded aggregation of ﬁlaments consisting of either
3R or 4R isoforms was only successful in cells expressing the
same isoform suggesting speciﬁcity in the assembly of
amyloid ﬁbers (Nonaka et al. 2010). Furthermore, two studies
have recently shown that tau can adopt different stable
conformational states that can propagate through recruitment
of native tau. Brain extracts from patients with different
tauopathies were able to induce differential patterns of spread
and tau deposition in mice (Sanders et al. 2014; Boluda et al.
2015). Similarly, inoculation with distinct tau strains produced
in vitro result in unique and consistent pathologies upon serial
passages in mice (Sanders et al. 2014), thus showing stable
conformational integrity analogous to prion strains. In addi-
tion, a recent biochemical analysis of pathological tau
aggregates from patient brains found distinct C-terminal band
patterns indicating disease speciﬁc conformations (Taniguchi-
Watanabe et al. 2016).
Similarly, distinct patterns of TDP-43 pathology have been
described. FTLD-TDP can be pathologically divided into four
subtypes (A–D), based on the predominant form of inclusions
found and each type is associated mostly with a certain disease
phenotype and often amutation in a speciﬁc FTLD-TDP related
gene (Mackenzie et al. 2011). For example, type A is deﬁned
by large amounts of short dystrophic neurites and oval-shaped
neuronal cytoplasmic inclusions and associated with bvFTD
andmutations in the progranulin gene. Some evidence suggests
that distinct structural conformations of TDP-43might underlie
these pathological subtypes (Tsuji et al. 2012). Different
mutations or post-translational modiﬁcations could introduce
variations in the protein fold that would further lead to
differences in the misfolded conformers. Distinct pathogenic
templates could have unique characteristics leading to cell or
region-speciﬁc preferences, varying propagation, and seeding
properties, and different levels of toxicity (Smethurst et al.
2015). Indeed, trypsin and chymotrypsin digestion of sarkosyl-
insoluble TDP-43 inclusions from patients produced speciﬁc
protease-resistant TDP-43 fragments leading to a distinct
banding pattern for subtypes A-C (Hasegawa et al. 2011;
Tsuji et al. 2012). Moreover, seeding aggregation with in vitro
aggregated synthetic TDP-43peptides (Shimonaka et al.2016)
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as well as homogenates from ALS and FTD patients (Nonaka
et al. 2013) in cell culture models resulted in various types of
pathologies showing the same distinct biochemical character-
istics as observed in the original seeds. Interestingly, seeded
aggregation required the interaction of the peptide seedwith the
identical peptide sequence of the host protein (Shimonaka et al.
2016). This indicates, that conformation-speciﬁc templating of
TDP-43 can lead to differentially misfolded conformers, which
furthermore can cause different patterns of pathology and
disease phenotypes in a strain-like manner.
In conclusion, prion-like phenomena may well explain the
heterogeneity in clinical and pathological presentation of FTD,
aswell as themolecular basis of disease progression and spread
in the nervous system. Further studies are needed to decipher
the particulars of this intriguing pathogenic pathway.
Conclusions and open questions
In conclusion, multiple lines of evidence support a template-
directed misfolding and propagation of pathology of FTD-
associated proteins, although the state of research varies for
each protein. Indeed, more evidence has accumulated over the
years for the propagation of tau, whose involvement in
neurodegeneration dates back to almost 20 years now (Hutton
et al. 1998), while much less is known for the more recently
identiﬁed TDP-43 (Neumann et al. 2006) and FUS (Kwiat-
kowski et al. 2009; Vance et al. 2009).
Several intriguing questions remain unanswered. Here, we
list some of those and propose potential experimental
approaches and key considerationswhen attempting to address
them.
What are the exact properties of the pathologic state?
Which of those define propagation and/or neurotoxicity?
Deﬁning structural properties of protein aggregates remains a
technologically challenging task, and few techniques can
reliably assess them. One of them is solid-state NMR, which
was used to deﬁne the beta-sheet core of aggregated tau
(Daebel et al. 2012), albeit no such studies have been reported
for TDP-43 or FUS, so far. Other techniques focusing on the
biophysical properties of protein assemblies that have been
used for prion particles (Laferriere et al. 2013), or more recent
assays based on detection of conformational protein changes
via mass spectrometry (Feng et al. 2014) may shed light to
these critical questions.
What is the role of post-translational modifications in
aggregation, seeding, and toxicity?
All FTD-associated proteins can be distinguished from their
native counterparts via speciﬁc post-translational modiﬁca-
tions (Fig. 1), which serve as markers for the detection of the
pathologic state in patient tissues. Yet the exact role of these
modiﬁcations in aggregation initiation seeding, spreading,
and toxicity remains unclear.
Can patient-derived or in vitro formed TDP-43 and/or FUS
aggregates trigger pathology and disease in experimental
animals?
Understanding the biophysical and structural features of
patient-derived aggregates is key for addressing this important
question. A potential challenge here is that these aggregates
most likely do not form beta-sheet conformations in patients,
so their mode of propagation may be entirely different from
prions and other classical amyloids. When attempting in vivo
inoculation experiments, onemust conﬁrm the preservation (in
the case of human brain-derived material) or faithful recon-
stitution (when using in vitro formed aggregates) of authentic,
patient-like pathologic conformation. The potential sequestra-
tion of RNA or other proteins within these pathologic
complexes may further complicate the issue.
Do any of these phenomena apply to dipeptide repeat
proteins accumulating in C9orf72 FTD?
While it is conceivable that dipeptide repeat proteins (Mori
et al. 2013), which originate from repeat-associated non-ATG
translation (Zu et al. 2011) speciﬁcally in C9orf72 hexanu-
cleotide repeat expansion carriers (DeJesus-Hernandez et al.
2011; Renton et al. 2011) may propagate and spread through-
out the brain, no experimental evidence exists currently to
support this. Similar to the other FTD-associated proteins,
dipeptide repeat proteins are forming insoluble aggregates,
which are neurotoxic in experimental models (Mizielinska
et al. 2014). Yet, they are conceptually distinct from tau, TDP-
43 andFUS, because of the lack of knownnative, stable protein
isoform, which would supply a constant source of substrate,
necessary for seeding and ampliﬁcation. This resembles the
case of polyglutamine and other repeat expansion diseases,
which intriguingly were shown to transport between neurons
(Pecho-Vrieseling et al. 2014; Brahic et al. 2016) and from
glia to neurons (Pearce et al. 2015) in a prion-like manner.
Can we capture the propagating entity to stall disease
progression in patients?
This is probably the most important question from the
viewpoint of FTD patients. Indeed, a major implication of
the spatiotemporal disease spread is the potential existence of
an extracellular ‘propagon’ that could be therapeutically
targeted and neutralized. Antibodies are excellent candidates
for this purpose and tau immunotherapy has been explored
with promising results (Funk et al. 2015; Sigurdsson 2016).
Similar approaches may prove effective for TDP-43 and FUS
proteinopathies in the future.
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